• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

MRE-269

CAS No. 475085-57-5

MRE-269 ( MRE-269; MRE269; MRE 269; ACT-333679 )

产品货号. M17517 CAS No. 475085-57-5

Ursonic acid belongs to the family of Ursane Triterpenes whose structure is based on the pentacyclic ursane skeleton. It has potential as HIV-1 Protease Inhibitor.

纯度: 98%

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
5MG ¥381 有现货
10MG ¥721 有现货
25MG ¥1158 有现货
50MG ¥1588 有现货
100MG ¥2673 有现货
200MG 获取报价 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    MRE-269
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    Ursonic acid belongs to the family of Ursane Triterpenes whose structure is based on the pentacyclic ursane skeleton. It has potential as HIV-1 Protease Inhibitor.
  • 产品描述
    MRE-269, also known as ACT-333679, is a long-acting and highly selective prostacyclin receptor agonist. MRE-269, the active form or metabolite of Selexipag (NS-304), is much more selective for the IP receptor than are the prostacyclin analogs beraprost and iloprost, which also have high affinity for the EP(3) receptor.
  • 同义词
    MRE-269; MRE269; MRE 269; ACT-333679
  • 通路
    Others
  • 靶点
    Other Targets
  • 受体
    HIV-1 protease
  • 研究领域
    Cardiovascular Disease
  • 适应症
    ——

化学信息

  • CAS Number
    475085-57-5
  • 分子量
    419.52
  • 分子式
    C25H29N3O3
  • 纯度
    98%
  • 溶解度
    DMSO : ≥ 50 mg/mL. 119.18 mM; H2O : < 0.1 mg/mL
  • SMILES
    CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(=O)C5(C)C)C)C)C2C1C)C)C(=O)O
  • 化学全称
    2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acid

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

产品手册
关联产品
  • R-7050

    R-7050 is a tumor necrosis factor receptor (TNFR) antagonist with greater selectivity toward TNFα.

  • Methyl nomilinate

    Methyl nomilinate from citrus can modulate cell cycle regulators to induce cytotoxicity in human colon cancer (SW480) cells in vitro.

  • HYOSCINE HYDROCHLORI...

    HYOSCINE HYDROCHLORIDE versus placebo in preventing motion sickness has been shown to be effective.